TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH COMBINED PATHOLOGY

TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH COMBINED PATHOLOGY

Combined pathology in patients with rheumatoid arthritis. Identification of the relationship with the effect of drug therapy.

Bibliographic Details
Main Authors:	D. I. Khusainova, B. A. Bakirov, G. R. Zaripova, L. N. Khusainova, E. M. Aitova, I. L. Bayanova, I. L. Muzaeva, G. A. Khakamova
Format:	Article
Language:	English
Published:	Science and Innovation Center Publishing House 2020-06-01
Series:	Siberian Journal of Life Sciences and Agriculture
Subjects:	ревматоидный артрит коморбидная патология генно-инженерные биологические препараты
Online Access:	http://journal-s.org/index.php/vmno/article/view/12726

Similar Items

Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01)

USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01)

Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01)

A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01)

Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
by: V. N. Amirdzhanova, et al.
Published: (2019-09-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

The prediction and long-term maintenance of low disease activity during therapy with disease modifying anti-inflammatory drugs for rheumatoid arthritis
by: E.L. Luchikhina
Published: (2014-05-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01)

Combination therapy with leflunomide and genetic engineering biological agents
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-06-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention
by: Natalia Vladimirovna Chichasova
Published: (2012-06-01)

POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
by: E. L. Luchikhina, et al.
Published: (2016-12-01)

Comorbid infections in patients with rheumatoid arthritis
by: B.S. Belov
Published: (2014-05-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

Treatment strategy for rheumatoid arthritis: hot topics
by: D. E. Karateev
Published: (2015-03-01)

Personalized medicine: Predictors for the efficiency of biological agent therapy for rheumatoid arthritis
by: M. A. Kotovskaya, et al.
Published: (2017-04-01)

OPTIMIZATION OF PHARMACEUTICAL CARE FOR JUVENILE RHEUMATOID ARTHRITIS AT THE REGIONAL LEVEL
by: A. A. Skripko, et al.
Published: (2018-01-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01)

Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

EFFICACY OF ABATACEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS REFRACTORY TO TNF-α
by: Yu. M. Spivakovskii, et al.
Published: (2015-04-01)

MANAGEMENT PROTOCOL FOR PATIENTS WITH JUVENILE ARTHRITIS
by: A. A. Baranov, et al.
Published: (2013-02-01)

Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
by: Irina Mikhailovna Marusenko
Published: (2013-12-01)

Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
by: A. V. Krasnopol’skaja, et al.
Published: (2015-11-01)

EFFECT OF «TREAT-TO-TARGET» ANTIRHEUMATIC THERAPY ON DIASTOLIC DYSFUNCTION OF THE LEFT AND RIGHT VENTRICLES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING 18 MONTHS OF OBSERVATION
by: I. G. Kirillova, et al.
Published: (2015-09-01)

RHEUMATIC DISEASES AND TUBERCULOSIS INFECTION IN CHILDREN AND ADULTS
by: G. V. Santalova, et al.
Published: (2019-03-01)

Infliximab in Russian clinical practice
by: G V Lukina, et al.
Published: (2012-09-01)

EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
by: O. Yu. Konopel'ko, et al.
Published: (2013-12-01)

Dactylitis in psoriatic arthritis: clinical features, diagnosis, immunopathogenesis, and treatment
by: T. V. Korotaeva, et al.
Published: (2018-04-01)

Efficacy and tolerability of adalimumab (humira) in patients with active rheumatoid arthritis
by: I G Salikhov, et al.
Published: (2010-12-01)

New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
by: A. E. Karateev, et al.
Published: (2022-12-01)

TREATMENT APPROACH FOR JUVENILE IDIOPATHIC ARTHRITIS-RELATED UVEITIS: 2012 UPDATE
by: Francesco Zulian, et al.
Published: (2012-09-01)